Hazal Aslan Rejeski
Overview
Explore the profile of Hazal Aslan Rejeski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
2
Citations
3
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Klauer L, Rejeski H, Ugur S, Rackl E, Abdulmajid J, Fischer Z, et al.
Int J Mol Sci
. 2025 Feb;
26(4).
PMID: 40004163
New therapies are highly needed to stabilize remission in patients with acute myeloid leukemia (AML). This study investigates the value of dendritic cells derived from leukemic blasts (DC) to enhance...
2.
Rejeski H, Hartz A, Rackl E, Li L, Schwepcke C, Rejeski K, et al.
Front Immunol
. 2025 Feb;
15:1527961.
PMID: 39949718
Acute myeloid leukemia (AML) remains a devastating diagnosis in clear need of therapeutic advances. Both targeted dendritic cells (DC) and particularly leukemia-derived dendritic cells (DC) can exert potent anti-leukemic activity....
3.
Rackl E, Hartz A, Rejeski H, Li L, Klauer L, Ugur S, et al.
Mol Immunol
. 2024 Sep;
175:40-54.
PMID: 39305847
T-cell receptor gamma delta (TCRγδ) expressing T-cells are known to mediate an MHC-independent immune response and could therefore qualify for immune therapies. We examined the influence of dendritic cells(DC)/antigen presenting...
4.
Unterfrauner M, Rejeski H, Hartz A, Bohlscheid S, Baudrexler T, Feng X, et al.
Int J Mol Sci
. 2023 Dec;
24(24).
PMID: 38139264
Although several (chemotherapeutic) protocols to treat acute myeloid leukemia (AML) are available, high rates of relapses in successfully treated patients occur. Strategies to stabilize remissions are greatly needed. The combination...